



## 5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)

<https://libcat.nshealth.ca/en/permalink/chpams35397>

Available Online: View Pamphlet

Corporate Author: Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program

Place of Publication: Halifax, NS

Publisher: Nova Scotia Health Authority

Date of Publication: 2022

Format: Pamphlet

Language: English

Physical Description: 1 electronic document (5 p.) : digital, PDF file

Subjects (MeSH): Inflammatory Bowel Diseases - drug therapy  
Crohn Disease - drug therapy  
Colitis - drug therapy

Subjects (LCSH): Inflammatory bowel diseases  
Crohn's disease  
Colitis

Abstract: 5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to control active ulcerative colitis, or Crohn's colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.

Notes: Previous title: 5-Aminosalicylate (5-ASA)

Responsibility: Prepared by: Nova Scotia Collaborative IBD Program

Pamphlet Number: 1483



## Ustekinumab (Stelara) therapy for Crohn's disease

<https://libcat.nshealth.ca/en/permalink/chpams35722>

Available Online: View Pamphlet

Corporate Author: Nova Scotia Health Authority. QEII. Gastroenterology

Place of Publication: Halifax, NS

Publisher: Nova Scotia Health Authority

Date of Publication: 2017

Format: Pamphlet

Language: English

Physical Description: 1 electronic document (9 p.) : digital, PDF file

Subjects (MeSH): Ustekinumab  
Crohn Disease - drug therapy

Subjects (LCSH): Crohn's disease  
Gastrointestinal agents

Abstract: Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn's disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.

Responsibility: Prepared by: Alison Harding BSc, Jennifer Stewart RN, CCRP, Dr. Des Leddin; Gastroenterology

Pamphlet Number: 1695



## Vedolizumab (Entyvio) therapy

<https://libcat.nshealth.ca/en/permalink/chpams35620>

**Available Online:** View Pamphlet

**Corporate Author:** Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program

**Place of Publication:** Halifax, NS

**Publisher:** Nova Scotia Health Authority

**Date of Publication:** 2022

**Format:** Pamphlet

**Language:** English

**Physical Description:** 1 electronic document (11 p.) : digital, PDF file

**Subjects (MeSH):** Gastrointestinal Agents  
Colitis, Ulcerative - drug therapy  
Crohn Disease - drug therapy

**Subjects (LCSH):** Gastrointestinal agents  
Ulcerative colitis  
Crohn's disease

**Specialty:** Medications

**Abstract:** Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.

**Responsibility:** Prepared by: Nova Scotia Collaborative IBD Program

**Pamphlet Number:** 1623